Jack Shiansong Li

Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study

Philip A. Philip, Jill Lacy, Fabienne Portales et al. · ˜The œLancet. Gastroenterology & hepatology · 2020 · 246 citations

Medicine, Oncology, Pharmacology +10

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer

E. Gabriela Chiorean, Daniel D. Von Hoff, Josep Tabernero et al. · British Journal of Cancer · 2016 · 90 citations · Full text

Medicine, Oncology, Pharmacology +14

Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered

Ellen S. de Morrée, Nicholas J. Vogelzang, Daniel P. Petrylak et al. · JAMA Oncology · 2016 · 41 citations

Medicine, Oncology, Pharmacology +17

Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT)

Arndt Vogel, Josefine Römmler-Zehrer, Jack Shiansong Li et al. · BMC Cancer · 2016 · 35 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase II LAPACT trial of <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC).

Pascal Hammel, Jill Lacy, Fabienne Portales et al. · Journal of Clinical Oncology · 2018 · 32 citations

Medicine, Oncology, Pharmacology +14